share_log

BTIG Initiates Coverage On ProMIS Neurosciences With Buy Rating, Announces Price Target of $8

Benzinga ·  Oct 3, 2023 16:43

BTIG analyst Thomas Shrader initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $8.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment